Haloperidol for the Treatment of Nausea and Vomiting in the ED

• Status: Not yet recruiting
• Trial end date: 2022-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ED) with a chief complaint of nausea or vomiting. A total of 300 patients age 18-55 presenting to the emergency department with chief complaint of nausea or vomiting will be enrolled from February 2021 - February 2022. Patients will be randomized and symptom levels will be recorded at 30, 60, 90, minutes. Follow-up will be performed by telephone at 24 hours.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Western Michigan University School of Medicine
• Treatments: Haloperidol; Haloperidol decanoate; Ondansetron

Criteria

Inclusion Criteria:

• presenting to the emergency department with chief complaint of nausea or vomiting

Exclusion Criteria:

• abnormal blood pressure (>200/100mmHg or <90/40mmHg),

• fever (>100.4F),

• acute trauma,

• QT > 450ms on cardiac monitor,

• altered mental status (GCS < 15),

• chest pain,

• known allergy to haloperidol or ondansetron,

• Parkinson's disease,

• pregnancy or lactation,

• use of any antiemetic in the previous 8 hours,

• nausea and vomiting associated with vertigo,

• prisoners or any wards of the state.